Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known about nutrient intake while using a GLP-1RA. The purpose of this study was to compare nutrient intake while using a GLP-1RA to the Dietary Reference Intakes (DRI). Methods: A cross-sectional study was conducted in a sample of participants who had been using GLP-1RA for at least one month ( N = 69). Participants answered online survey questionnaires and completed a 3-day food record. Descriptive statistics (means, standard deviations) were calculated for all participant demographic characteristics and average 3-day nutrient intakes. Average 3-day nutrient intakes were compared to the DRI using 95% confidence intervals (CI). A Bonferroni correction applied accepted significance at p ≤ 0.00156. One-way ANOVA analysis was conducted to compare the self-reported MyPlate servings to recorded servings from the 3-day food record. Results: Compared to the DRI reference values, participants consumed adequate amounts of B-vitamins, copper, phosphorus, selenium, and zinc. Participants had insufficient intakes of several key nutrients below the DRI, including fiber (14.5 g; CI: 12–17), calcium (863 mg; CI: 756–970), iron (12.1 mg; CI: 11–13), magnesium (266 mg; CI: 236–297), potassium (2,186 mg; CI: 1,969–2,402), choline (305 mg; CI: 268–342), vitamin A (560 mcg RAE; CI: 469–651), vitamin C (51 mg; CI: 41–61), vitamin D (4 mcg; CI: 3–5), vitamin E (9.6 mg; CI: 8–11), and p < 0.00156. Participants overconsumed % calories from fat (39.9%; CI: 38, 42), and saturated fat (26 g; CI: 26, 26), p < 0.00156. Participants did not meet the daily recommended MyPlate servings for fruit, vegetables, grains, or dairy ( p < 0.01). Protein intake (% total calories) was within the AMDR, however based on a g/kg/day, protein intake was significantly under daily needs. Conclusion: Participants on a GLP-1RA are not meeting the DRI for several vital nutrients through their diet or higher protein needs during weight loss. Patient-centered nutritional guidance is essential to optimize health outcomes and prevent unintended health consequences. Future large-scale studies are needed to assess the replicability of these findings and provide custom nutritional guidance for those on a GLP-1RA medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“72% consumed energy below estimated needs”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A cross-sectional study of 99 participants shows that AOMs users consume an unbalanced diet, with excessive calories from saturated fatty acids, inadequate calories from carbohydrates, and a lack of micronutrients, especially vitamin D [66].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“According to recent studies, following AOM treatment, individuals often exhibit inadequate intake or deficiencies of several micronutrients such as retinol, vitamin E, vitamin C, magnesium, B1, B12, iron, zinc, and especially vitamin D, calcium, and B9 [66,68,74].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“54% consumed protein < 0.8 g/kg/day; 43% met ≥ 1.2 g/kg/day, only 10% ≥ 1.6 g/kg/day”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The observational studies embedded within clinical trials and those using other study designs provided important insights into appetite regulation and habitual dietary intake during incretin therapy, despite the absence of structured nutrition interventions or dietitian support [5, 6, 13, 14, 20].”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [20]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Dietary assessment methods in epidemiologic studies
Shim, J.-S., Oh, K., & Kim, H. C. (2014) · Epidemiology and Health · doi:10.4178/epih/e2014009 · Cited by 1,545 · cited 3×
“Dietary assessments used in research have inherent strengths and limitations (26), however, the 3-day food record was selected to help identify key knowledge gaps related to dietary intake among patients using GLP-1RA (29).”
InfluentialSubar, A. F., Kirkpatrick, S. I., Mittl, B., Zimmerman, T. P., Thompson, F. E., Bingley, C., Willis, G., Islam, N. G., Baranowski, T., McNutt, S., et al. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.04.016 · Cited by 934
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 1×
“Another study evaluated ad libitum intake during week 12 of Semaglutide treatment and found a 24% reduction in total calories compared to placebo for the one-day energy intake measured in a feeding lab (23).”
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Chiavaroli, L., Viguiliouk, E., Nishi, S., Blanco Mejia, S., Rahelić, D., Kahleová, H., Salas-Salvadó, J., Kendall, C., & Sievenpiper, J. (2019) · Nutrients · doi:10.3390/nu11020338 · Cited by 548
The role of protein in weight loss and maintenance
Leidy, H. J., Clifton, P. M., Astrup, A., Wycherley, T. P., Westerterp-Plantenga, M. S., Luscombe-Marsh, N. D., Woods, S. C., & Mattes, R. D. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.084038 · Cited by 475 · cited 2×
“Several publications emphasize the importance of and critical need for high-protein diets during weight loss (14–16).”
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Garrow, J. S., & Summerbell, C. (1995) · PubMed · Cited by 415
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358
Research works printed but not linked: 5
- 2024, Obesity and overweight [internet]
- 2025, Report on clinical practice guidelines for nutrition in obesity [internet]
- 2020, Dietary guidelines for Americans
- 2025, ASA24
- Wharton, 2021, Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice, Postgrad Med, 134, 14, 10.1080/00325481.2021.2002616 · DOI · Paper page
Cited by
Urbina, J., Salinas‐Ruiz, L. E., Valenciano, C., & Clapp, B. (2026) · Clinical Obesity · doi:10.1111/cob.70070 · Cited by 40
“Average intakes were 60%–75% below DRI targets, with fewer than 10% of participants meeting the recommended levels [8].”
Muscle loss and GLP-1R agonists use
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31
“…in a recent cross-sectional analysis of GLP-1RAs users, only 43% of participants achieved the minimum recommended intake of 1.2 g/kg/day, with 10% reaching higher targets such as 1.6–2.0 g /kg/day, and with an average protein consumption accounting for just 18–19% of daily energy intake [43].”
InfluentialSibal, R., Balamurugan, G., Langley, J., Graham, Y., & Mahawar, K. K. (2025) · Nutrients · doi:10.3390/nu17233659 · Cited by 30
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
“In this context, a focus on weight loss alone is not enough: MNT becomes essential to support treatment out - comes, ensuring nutritional adequacy fundamental to support metabolic health and preserve MM during semaglutide treat-ment [85 ].”
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18
“In addition to micronutrient status, the loss of muscle mass may be significantly higher when using GLP-1 RA than with traditional weight loss programs involving diet and exercise [35,36].”
Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025) · Nutrients · doi:10.3390/nu17111934 · Cited by 16
“A recent exploratory study found that participants commonly failed to meet dietary reference intakes (DRIs) for calcium, magnesium, potassium, vitamin D, iron, fiber, and choline, while overconsuming saturated fat and sodium [40].”
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
Johnson, B. V. B., Milstead, M., Kreider, R., & Jones, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100209 · Cited by 27
“Previous research indicates that those on GLP-1RA are not consuming adequate daily servings of fruits, vegetables, and antioxidant nutrients such as vitamins C and E [17].”
InfluentialSelf-citationBen‐Porat, T., Dagan, S. S., Côté, M., Miner, C. J., & Buch, A. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100522 · Cited by 18
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
“The appetite suppressive effects of obesity medications lead to caloric reduction (188,189), and this reduced food consumption may be insufficient to meet essential micronutrient requirements in some individuals (190,191).”
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“AOMs cause rapid and significant weight loss, higher and faster than traditional weight loss by diet and exercise, and offer a real and valid alternative to BS [66].”
InfluentialJohnson, B. V. B., Milstead, M., Green, L., Kreider, R., & Jones, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100195 · Cited by 26
“This study was a secondary analysis of a cross-sectional study conducted in a group of individuals currently using a GLP-1RA living in the United States [U.S.] [19].”
InfluentialSelf-citation(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“…RA for at least one month showed that 75% of participants reported having increased their protein intake after treatment, yet only 43% achieved the recommended intake of ≥ 1.2 g/kg/day; fiber, vegetable, and fruit intake remained inadequate, while saturated fat and sodium intake were high [ 111].”
InfluentialWang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“In addition, the delay in gastric emptying caused by GLP-1RA and changes in gut microbiota might impact the metabolism and absorption of micronutrients [61, 62].”
Mehta, M., Rometo, D. A., Gusenoff, J. A., & Rubin, J. P. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012672 · Cited by 16
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 9
“While this effect facilitates adherence to energy restriction and supports weight loss, it also introduces a risk of insufficient protein, fiber, and fluid intake when meals are skipped or substantially reduced in size [46].”
Ponzo, V., Vitale, M., Bo, S., Broglio, F., Goitre, I., & Cioffi, I. (2025) · Nutrients · doi:10.3390/nu17213318 · Cited by 6
Alharbi, S., & Alkhalifah, A. (2026) · Skin Appendage Disorders · doi:10.1159/000550540 · Cited by 6
“Johnson et al. [27] (2025) provided more granular data, documenting alarming deficiency rates in 69 GLP-1 users: 98.6% vitamin D deficiency, 88.4% iron deficiency, 89.9% magnesium deficiency, and 75% consuming inadequate protein ( < 1.2 g/kg/day needed during weight loss).”
InfluentialMicronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
Koceva, A., Janež, A., Pečko, T., & Jensterle, M. (2026) · Nutrients · doi:10.3390/nu18040677 · Cited by 7
“Dietary fiber intake was also inadequate, and protein intake was also below levels commonly recommended for lean mass preservation during weight loss, with only 10% meeting a protein intake of at least 1.6 g/kg/day [31].”
InfluentialMind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment
Hubert, P. A., Coleman, C. D., Grosicki, G. J., Kiel, J., Shepherd, M., Lofton, H. F., Heymsfield, S. B., Thomas, J. G., Dhurandhar, N. V., & Jonnalagadda, S. S. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156366 · Cited by 5
GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Șufaru, I.-G., Vasiliu, B. C., Hăncianu, M., Stratul, Ş., Tatarciuc, M., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., et al. (2026) · Biomolecules · doi:10.3390/biom16060857 · Cited by 6
“…evidence warrants concern about reduced intake and nutritional imbalance during therapy, but most studies focus on obesity or nutrition, and very few assess periodontal surgery, regenerative procedures, or peri-implant healing directly in relation to dietary changes during GLP-1RA use [163].”
Cozma, D. C., Văcărescu, C., & Stoicescu, C. I. (2025) · Biomedicines · doi:10.3390/biomedicines13123079 · Cited by 5
“Incorporating resistance exercise alongside targeted nutrition further enhances anabolic signaling, mitigating the risk of sarcopenia while optimizing the therapeutic synergy of pharmacological and lifestyle interventions [30,31].”
Rodriguez, W. A. C., Rodríguez-Yparraguirre, A. J., Yparraguirre, C. D. R., Vásquez, W. A. M., Espino, I. M. O., Epifanía-Huerta, A., Lara-Rivera, O., Guarniz-Vásquez, E. M., Moreno-Rojo, C., & Aguirre, E. (2026) · Foods · doi:10.3390/foods15030425 · Cited by 4
“In studies with fermented quinoa, peptides exhibiting angiotensin-converting enzyme (ACE) inhibitory activity have been identified, opening possibilities for the development of functional foods with antihypertensive effects [83].”
Rutigliani, G., & Mattes, R. D. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115486 · Cited by 4
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“Johnson et al., in a cross-sectional study of 69 adults using incretin-based therapy, reported iron intake below dietary reference levels in a substantial proportion of participants, alongside low intake of vegetables, grains, dairy, and other nutrient-dense foods [109].”
InfluentialFeraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
“Evidence suggests that beyond total protein intake, nutritional timing and protein quality are critical determinants of muscle preservation in patients undergo - ing pharmacological weight-loss therapy [94 , 111 ].”
Yang, Q., Wang, Y., Gao, G., Li, H., Gao, Y., & He, J. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02133-z · Cited by 2
“A cross-sectional study of GLP-1RA users also found that the protein intake of the participants was significantly lower than the daily requirement [67].”
Infante, M., Ricordi, C., Pacifici, F., Pastore, D., Infante, R., Caprio, M., Chiereghin, F., Stefano, A. D., Frank, G., Rose, A. D., et al. (2026) · Nutrients · doi:10.3390/nu18132038 · Cited by 3
“Johnson et al. [45] conducted a cross-sectional study on 69 subjects who had been using GLP-1 RA and the dual GIP/GLP-1 receptor agonist tirzepatide for weight management for at least one month and who completed a 3-day food record to assess micronutrient intake relative to Dietary Reference…”
InfluentialGlucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms
Spindler, A. J., Maas, D., Rachko, G., Zappi, I., Kapur, S. K., Sidhu, K. S., Maas, K., Garza-García, L. M., Patrocínio, J., Petukhova, L., et al. (2026) · JAAD reviews. · doi:10.1016/j.jdrv.2026.07.002 · Cited by 2
Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy
Belančić, A., Skroče, K., Gkrinia, E. M. M., Glavić, M. M., & Kwok, M. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155870 · Cited by 3
“Weekly tracking via apps (e.g., MyFitnessPal), dietitian consults, and biomarkers (e.g., 3-methylhistidine for catabolism) enable adherence, with >75% self-reporting increased protein post-initiation, but objective shortfalls are prevalent [74,77].”
Obesity and Iron Metabolism: Mechanisms, Status Assessment, and Clinical Implications
Aguree, S., & Meng, X. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00753-0 · Cited by 2
“Early dietary studies suggest that many users may fall short of the recommended protein and micronutrient intake during treatment [ 75, 76 ].”
Ibsen, D. B., Kobayashi, R., Bruun, J. M., & Drouin‐Chartier, J. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.07.040 · Cited by 1
Johnson, B. V. B. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101436 · Cited by 1
Self-citationExtending Healthspan via GLP-1 Receptor Agonist: Insights and Perspectives
Chakrabarti, S. K., & Chattopadhyay, D. (2026) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2025.00036 · Cited by 1
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
“Observations of variable lean mass outcomes and dietary shifts during GLP-1RA therapy [ 40 , 75] suggest that substrate availability may influence therapeutic durability even in the absence of overt deficiency.”
InfluentialObesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Hong, K. M., SULO, S. S., Wang, W., Kim, M., Hong, L., Kerr, K. W., Fan, L., & Williams, D. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s574765 · Cited by 1
da Cruz, M. R. R., Cabral, K., & Marques, L. (2026) · Medical Research Archives · doi:10.18103/mra.v14i5.7498 · Cited by 2
Narla, S., & Narla, R. R. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.07.030 · Cited by 1
Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care
Cozma-Petruț, A. P., Gherghel, M., Banc, R., Tișa, I. B., Stanciu, O., Coldea, T. E., Mudura, E., Miere, D., & Filip, L. A. (2026) · Nutrients · doi:10.3390/nu18162691 · Cited by 1
“…should be individualized according to age, sex, body weight, physical activity level, and treatment response, while excessively restrictive dietary approaches may increase the risk of dehydration, electrolyte imbalance, gallstone formation, and inadequate nutrient intake [152,163,164].”
Response to Letter to the Editor
(2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100215
DeCan, C. L., Thure, K. A., & Ma, M. (2025) · Journal of the American Nutrition Association · doi:10.1080/27697061.2025.2568073 · Cited by 2
Einfluss von GLP-1-Analoga auf die Mikronährstoffversorgung
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Ernährung & Medizin · doi:10.1055/a-2492-9615
“Dies führt letztlich zu einer signifikanten Verminderung der Nah - rungs-und Energieaufnahme um bis zu 40 % [13, 14] und in der Folge zu deutlichen Gewichtsverlusten, die zwischen Liraglutid und Semaglutid variieren [6, 15, 16].”
58 risk and 34 protective effects of GLP1R on disease phenome and adverse neonatal healthPreprint
Campbell, R. H., & Mills, M. C. (2026) · medRxiv · doi:10.64898/2026.01.24.26344404
Seibert, I. (2026) · Research in Therapeutic Sciences · doi:10.53520/rts2026.105184
O'Keeffe, M., Pena-Altamira, E., Shuriye, S., Dunk, D., Canfell, O. J., White, R., & Duncan, A. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70215
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731
“Interestingly, participants met DRIs for most B-vitamins, copper, phosphorus, selenium, and zinc [65].”
InfluentialWithrow, N. A., Hsueh, E. E., Wolever, T., Jenkins, A. L., Campbell, J. C., Zurbau, A., McMahon, R., & Valentine, C. J. (2026) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2026.109393
“Evidence indicates that individuals on GLP-1RA therapy often reduce total energy intake by 16% to 39%, leading to a substantial loss of lean body mass (LBM) [6].”
Čermáková, E. (2026) · Medicína pro praxi · doi:10.36290/med.2026.025
Babazadeh, D., Therrien, S., Fitch, A., & Steinberg, F. M. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100292 · Cited by 1
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Peripheral nerve complications from medications utilised for weight loss: a systematic review
O’Gorman, C., O’Gorman, M., & Warren, N. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14048-w
“This may be furthered by medication induced caloric reduction and subsequent failure to meet nutrient dietary intake, altered gastric transit and unchanged poorly nutritive dietary intake patterns [77–79].”
Choline and metabolic health, a missing link in a critical chain
Paules, E. M. (2026) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001252
Balasubaramaniam, V., Scobie, M., O’Kane, M. P. M., Graham, Y., Robertson, A. G., & Mahawar, K. K. (2026) · Nutrients · doi:10.3390/nu18162643
“These include a significant reduction in intake that may decrease not only energy intake but also protein, fibre, fluid, vitamin, and mineral intake [9–12].”
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
“Reported intake among GLP-1RA users brings these consequences into sharper focus, with shortfalls in fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E and protein intake per kilogram often below levels commonly targeted during weight loss (73).”
GLP-1 Receptor Agonist Use in Cancer Survivors—Challenges and Opportunities: A Narrative Review
Agurs‐Collins, T., & Sauter, E. R. (2026) · Cancers · doi:10.3390/cancers18162714
“In addition, one study reported that individuals using GLP-1 medicines consumed insufficient amounts of essential nutrients and had suboptimal protein intake during weight loss [66], thereby increasing their risk of protein-energy malnutrition.”
Sorić, T., Sarić, A., Ivanišin, A., Lovrić, M., Milić, M., Matovinović, M., & Sarić, M. M. (2026) · Nutrients · doi:10.3390/nu18172757 · Cited by 2
“Evidence describing shifts in dietary patterns, food-group consumption, and nutrient intake during GLP-1 therapy remains surprisingly limited, despite the widespread use of these medications [16,24,33].”
InfluentialMedina, N. G., Cui, Y., Chen, D. Q., Fayyaz, M., Xu, F., Mirshafeeyan, M., & Smith, A. M. (2026) · ACS Nano · doi:10.1021/acsnano.6c00432
Kavsara, H. K. (2026) · Journal of Medical Topics and Updates · doi:10.58651/jomtu.1980569
Cautela, D., Valeria, I., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188057
“Cross-sectional data demonstrate that the majority of GLP-1RA users do not meet the recommended protein targets [104,105].”
Mizdrak, M., Batistic, D., & Mizdrak, I. (2026) · Medical Sciences · doi:10.3390/medsci14050577
“Prolonged satiety and food aversion may lead to monotonous diets [60,61] and reduced consumption of iron-dense foods [62].”
Schipper, R. M., Heusschen, L., Schepers, L., Verstraete, F. F., Hazebroek, E. J., Kampman, E., & Berendsen, A. A. M. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119119
Improving Medication Classification in GLP‐1RA Research: Feasibility of a Photo‐Review Protocol
Katz, J. M., Gearhardt, A. N., & Hafez, D. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70200
Balvers, M. G. J., de Smit, T. L., Slotegraaf, A. I., Bemelmans, R. H. H., Kolkert, J. L., Schuijt, T. J., & Witkamp, R. F. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70307
“Johnson and co-workers reported insufficient intakes for vitamin A, C, D and E but reported adequate intakes of B vitamins [43].”
Kwaśny, A., Słoma-Krześlak, M., Kostelecki, G., Rychter, A. M., Brzegowy, M., Jeziorek, M., Kręgielska-Narożna, M., Lange, E., Boniecka, I., Prejbisz, A., et al. (2026) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/235937
Dézsi, C., Gulyás-Oldal, V., Paschali, E., Gálóczi, I., Nagy, S., & Szili, K. (2026) · Nutrients · doi:10.3390/nu18193259
“In the same people, protein was within the acceptable macronutrient distribution range as a percentage of energy but below requirement in g/kg [102].”
Schwartzberg, E., Azran, C., Diker‐Cohen, T., Shani, S., & Dotan, I. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100867
“27,55,56 • Iron: GLP1-RAs may reduce iron absorption, increasing the risk of iron deficiency anemia 27,55,56”
Lim, D., Hawton, K., Dias, R. P., Aswani, N., Steele, C. A., Sachdev, P., Peacock, A., Robertson, S., Marshall, A. S. J., Tang, W., et al. (2026) · Archives of Disease in Childhood · doi:10.1136/archdischild-2026-330728
Metadata
- Authors
- Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R.
- Corresponding author
- Johnson, Brittany
- ORCID
- Milstead, Mary
- Venue
- Frontiers in Nutrition
- Publisher
- Frontiers Media SA
- Published
- 2025-04-25
- Volume
- 12
- Pages
- 1566498-1566498
- ISSN
- 2296-861X (ISSN-L)
- PMC
- PMC12062175
- OpenAlex
- W4409825229
- Cited by
- 64
- References
- 38
- Citations by year
- 2026: 46 · 2025: 18
- FWCI
- 36.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Nutrition (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Nutrition, Health and Food Behavior
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, nutrient intake, obesity treatment, Dietary Reference Intakes, MyPlate, dietary fiber, calcium intake, iron intake, dietary magnesium, potassium intake, vitamin D, saturated fat, macronutrient distribution, food diary, micronutrient adequacy, dietary adherence, anti-obesity drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.